These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38676808)

  • 1. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
    Roberts A; Hallet J; Nguyen L; Coburn N; Wright FC; Gandhi S; Jerzak K; Eisen A; Look Hong NJ
    Breast Cancer Res Treat; 2024 Jul; 206(2):227-244. PubMed ID: 38676808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Location of Residence and Distance to Cancer Centre on Medical Oncology Consultation and Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
    Yee EK; Hallet J; Look Hong NJ; Nguyen L; Coburn N; Wright FC; Gandhi S; Jerzak KJ; Eisen A; Roberts A
    Curr Oncol; 2024 Aug; 31(8):4728-4745. PubMed ID: 39195336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database.
    Cheng H; Dai Q; Liu G; Tong X; Wang Y
    Clin Breast Cancer; 2024 Oct; 24(7):e593-e599. PubMed ID: 38890023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
    Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T
    Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
    Zhang H; Barner JC; Moczygemba LR; Rascati KL; Park C; Kodali D
    Breast Cancer Res Treat; 2022 Jun; 193(3):695-705. PubMed ID: 35449473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
    Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
    Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
    Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
    Livingston-Rosanoff D; Schumacher J; Vande Walle K; Stankowski-Drengler T; Greenberg CC; Neuman H; Wilke LG
    Clin Breast Cancer; 2019 Dec; 19(6):e741-e747. PubMed ID: 31300338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
    Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
    O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
    Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.